Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies with an immunochromatographic device: a prospective single-center study

AbstractObjectivesSARS-CoV-2 infection diagnosis is challenging in patients from 2-3 weeks after the onset of symptoms, due to the low positivity rate of the PCR. Serologic tests could be complementary to PCR in these situations. The aim of our study was to analyze the diagnostic performance of one serologic rapid test in COVID-19 patients.MethodsWe evaluated an immunochromatographic test (AllTest COVID-19 IgG / IgM) which detects IgG and IgM antibodies. We validated the serologic test using serum samples from 45 negative patients (group 1) and 55 patients with COVID-19 confirmed by PCR (group 2). Then, we prospectively evaluated the test in 63 patients with clinical diagnosis of pneumonia of unknown etiology that were COVID-19 negative by PCR (group 3).ResultsAll 45 patients from group 1 were negative for the serologic test (specificity = 100%). Regarding group 2 (PCR-positive), the median time from their symptom onset until testing was 11 days. For these 55 group-2 patients, the test was positive for either IgM or IgG in 26 (overall sensitivity = 47%), and in patients tested 14 days or more after the onset of symptoms, the sensitivity was 74%. Regarding the 63 group-3 patients, median time after symptom onset was 17 days, and the test was positive in 56 (89% positivity).ConclusionsOur study shows that serologic rapid tests could be used as a complement of PCR to diagnose SARS-CoV-2 infection after 14 days from the onset of symptoms and in patients with pneumonia and negative PCR for SARS-CoV-2.

Download Full-text

Evaluation of the TGS TA system for the detection of anti-Toxoplasma antibodies

Microbiologia Medica ◽

10.4081/mm.2017.6583 ◽

2017 ◽

Vol 32 (1) ◽

Author(s):

Olivia Arpino ◽

Annalisa Cianflone ◽

Maria Teresa Manco ◽

Alessia Paganini ◽

Massimo De Paschale ◽

...

Keyword(s):

High Avidity ◽

Past Infection ◽

Recent Infection ◽

Igm Antibodies ◽

Igg Avidity ◽

Avidity Test ◽

Group 3 ◽

Group 2 ◽

Group 1

Background and aims. The aim of the present study was to evaluate the new chemiluminescence TGS TA system of Technogenetics (Milan, Italy) for detecting anti-Toxoplasma IgG and IgM antibodies and IgG avidity. The TGS TA system was compared with our chemiluminescence routinely used system, LIAISON XL, supplied by Diasorin (Saluggia, Italy), for the detection of IgG and IgM antibodies. Only in positive IgM samples (retrospective study) and for the IgG avidity (if existent), TGS TA system was compared to an Enzyme Linked Fluorescent Assay (ELFA) test (VIDAS, BioMérieux, Marcy-l’Étoile, France). Materials and methods. Three hundred and one sera samples, from women who came to our centre for the routine follow up pregnancy, were examined with the TGS TA system and divided in 3 groups according to IgG and IgM screening LIAISON XL tests: 106 were non-immune women (Group 1), 100 were pregnant with past infection (Group 2) and 95 were pregnant with positive or equivocal IgM (82 with positive IgG and 13 with negative IgG) (Group 3). Results. The overall concordance of the IgG results between LIAISON XL and TGS TA was 99.3%: 100% in Group 1, 98% in Group 2 and 100% in Group 3. The overall concordance of the IgM results between LIAISON XL and TGS TA was 93.9%: 100% in Group 1, 94% in Group 2 and 82.8% in Group 3. In Group 3, the concordance between the results of the IgG avidity with the ELFA and TGS TA tests was 81.7%. Comparing the clinical diagnosis obtained with our protocol and that of the TGS TA system, the overall concordance was 92.7%: 100% in Group 1, 92.0% in Group 2 and 78.9% in Group 3. Conclusions. The overall concordance of IgG antibodies is excellent for both protocols while for IgM antibodies is very high in the first group and lower in the third group, due to the presence of non-specific IgM subjects in this group. The TGS TA avidity test seems to predict ealier the maturation of the IgG compared to the ELFA test since many samples with low avidity with the ELFA were seen with moderate avidity with TGS TA and all those with borderline avidity with the ELFA were seen with high avidity with TGS TA. This system shows to be a valuable tool with overall good clinical correlation and able to clearly identify nonspecific subjects, those with a non-recent infection.

Download Full-text

Evaluation of the TGS TA system for the detection of anti-rubella antibodies

Microbiologia Medica ◽

10.4081/mm.2017.6582 ◽

2017 ◽

Vol 32 (2) ◽

Author(s):

Olivia Arpino ◽

Annalisa Cianflone ◽

Maria Teresa Manco ◽

Alessia Paganini ◽

Massimo De Paschale ◽

...

Keyword(s):

Elisa Test ◽

Childbearing Age ◽

Past Infection ◽

Recent Infection ◽

Igm Antibodies ◽

Igg Avidity ◽

Group 3 ◽

Group 2 ◽

Sera Samples ◽

Group 1

Background and aims: The aim of the present study was to evaluate the new Technogenetics TGS TA system for detecting antirubella IgG and IgM antibodies and IgG avidity. TGS TA system was compared with our routinely used system, LIAISON XL, for the detection of IgG and IgM antibodies. Only in positive IgM samples (retrospective study), TGS TA system was compared to an ELFA IgM test and with an ELISA test for the IgG avidity (if existent). Materials and methods: Two hundred and seventy six sera samples from women were examined with TGS TA system and divided in 3 groups according to IgG and IgM screening LIAISON XL tests: 112 were of childbearing age and non-immune women (Group 1), 106 were pregnant with past infection or vaccinated (Group 2) and 49 were pregnant with positive or equivocal IgM (Group 3). Results: The overall concordance of the IgG results between LIAISON XL and TGS TA was 93.3%: 86.6% in Group 1, 97.2% in Group 2 and 100% in Group 3. The overall concordance of the IgM results between LIAISON XL and TGS TA was 89.0%: 100% in Group 1, 100% in Group 2 and 35.6% in Group 3. In Group 3, the concordance between the results of the IgG avidity with the ELISA and TGS TA tests was 85.7%. Comparing the clinical diagnosis obtained with our protocol and that of the TGS TA system, the overall concordance was 97.4%: 86.6% in Group 1, 97.2% in Group 2 and 85.7% in Group 3. Conclusions: TGA TS system shows to be a valuable tool with overall good clinical correlation and able to clearly identify nonspecific subjects, those with a non-recent infection or those who are vaccinated. The TGS TA test also seems to be especially sensitive in indicating vaccinated subjects with low IgG levels as immune.

Download Full-text

A comparison between different anti-retroviral therapy regimes on soluble inflammation markers: a pilot study

AIDS Research and Therapy ◽

10.1186/s12981-020-00316-w ◽

2020 ◽

Vol 17 (1) ◽

Author(s):

Martina Maritati ◽

Trentini Alessandro ◽

Nunzia Zanotta ◽

Manola Comar ◽

Tiziana Bellini ◽

...

Keyword(s):

Drug Regimen ◽

Antiretroviral Drugs ◽

Serum Samples ◽

The Third ◽

Cytokines And Chemokines ◽

Antiretroviral Drug ◽

Group 3 ◽

Group 2 ◽

Inflammatory Profile ◽

Group 1

Abstract Background Although HIV-related deaths have decreased dramatically following the introduction of antiretroviral therapy (ART), HIV infection itself causes increased morbidity and mortality for both non-AIDS-related events or chronic inflammation and immune activation. The use of certain antiretroviral drugs can contribute to this process. Methods We investigated 26 potential biomarkers in serum samples from HIV-1 infected patients virologically suppressed under ART. The main objective of our study was to evaluate if virological suppression achieved with a triple drug regimen containing tenofovir disoproxil fumarate co-formulated with emtricitabine (TDF/FTC) as backbone, could correlate with a better immunological and inflammatory profile in relation to the third class of antiretroviral drug administered. The eligible patients were then divided into 3 groups in relation to the third drug associated with TDF/FTC: nucleoside reverse transcriptase inhibitors (NNRTI) (Group 1, n = 16), protease inhibitors (PI) (Group 2, n = 17) and integrase inhibitors (INI) (Group 3, n = 16). Results Inflammatory cytokines and chemokines were more represented in Group 2 than in Group 3 (IL-1Ra, p = 0.013; IL-12p70 p = 0.039; TNF-α p = 0.041; IL-8, p = 0.027; MIP1 β, p = 0.033). Eotaxin showed lower levels in Group 1 compared to Group 2 (p = 0.010), while IP-10 was significantly lower in Group 1 compared to both Group 2 and Group 3 (p = 0.003 and p = 0.007, respectively). Conclusions Our results seem to discourage the administration of PI as a third drug in a virologically effective antiretroviral regimen, as its use is linked to the detection of higher levels of pro-inflammatory mediators in comparison with INI and NNRTI.

Download Full-text

Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial

Blood ◽

10.1182/blood.v112.11.54.54 ◽

2008 ◽

Vol 112 (11) ◽

pp. 54-54 ◽

Cited By ~ 9

Author(s):

Yves Beguin ◽

Johan Maertens ◽

Bernard De Prijck ◽

Rik Schots ◽

Pascale Frere ◽

...

Keyword(s):

Median Time ◽

Darbepoetin Alfa ◽

Transferrin Saturation ◽

Iron Sucrose ◽

Highly Effective ◽

Group 3 ◽

Group 2 ◽

Autologous Hct ◽

The Impact ◽

Group 1

Abstract Background : We previously reported a retrospective study suggesting that erythropoietin therapy starting on day 28 after autologous HCT was highly effective to improve Hb levels and that i.v. iron might improve response in patients with low transferrin saturation (Baron et al., Clin Cancer Res 2003). This prompted us to conduct a multicenter prospective randomized study analyzing the impact of darbepoetin alfa with or without i.v. iron on erythroid recovery after autologous HCT. Patients and Methods : 127 autologous HCT recipients with lymphoid malignancies were randomized 1:2:2 between no treatment (group 1, n=25), darbepoetin alfa (Aranesp®) 300 μg QOW starting on day 28 after HCT for a total of 7 doses (group 2, n=52), or the same regimen of darbepoetin alfa plus i.v. iron sucrose (Venofer®) 200 mg on days 28, 42 and 56 after HCT (group 3, n=50). Once the target Hb (13 g/dL) was attained, the dose of darbepoetin alfa was reduced to 150 μg, while it was withheld when Hb was ≥ 14 g/dL. Primary endpoints included proportion of complete correctors (i.e. patients reaching Hb □ 13 g/dL) before day 126 post-transplant and median time to achieve Hb correction in each arm. Data were analyzed following the intention-to-treat principle. The proportion of complete correctors by day 126 in each group was compared using the Fisher’s exact test, and median times to reach 13 g/dL in each group were compared using the logrank test. Results : The proportion of complete correctors was 24% in group 1, 81% in group 2 (P<0.001 compared with group 1), and 92% in group 3 (P<0.001 compared to group 1, and P=0.099 compared to group 2). Median time to achieve Hb □ 13 g/dL was not reached in group 1, 42 days in group 2 (P<0.001 compared to group 1), and 32 days in group 3 (P<0.001 compared to group 1 and P=0.127 compared to group 2) (Fig 1A). Hb evolution in each group is shown in Fig 1B. Mean ± standard deviation total doses of darbepoetin-alfa administered were 1,445 ± 489 μg in group 2 vs 1,272 ± 443 μg in group 3 (P=0.06). Ferritin levels at the end of study were 477 ± 597, 393 ± 599 and 479 ± 488 in groups 1, 2 and 3, respectively (NS). Eight patients (2 in group 1, 4 in group 2, and 2 in group 3) required red blood cell transfusions on study, including 4 patients following early disease progression. There was no difference in rates of thrombo-embolic events or other complications among the groups. Quality-of-life data will be presented. Conclusions : This is the first prospective randomized trial demonstrating that darbepoetin alfa is safe and highly effective to ensure full erythroid reconstitution after autologous HCT when started on day 28 posttransplant. I.v. iron sucrose tended (not statistically significant) to further fasten erythroid recovery with a lower dose of darbepoetin alfa required. Future studies in this setting should aim at further investigating the impact i.v. iron might have on improving response in patients with low transferrin saturation. Figure 1. Figure 1.

Download Full-text

Increased serum interleukin-9 and interleukin-1β are associated with depression in type 2 diabetes patients

Arquivos de Neuro-Psiquiatria ◽

10.1590/0004-282x20190177 ◽

2020 ◽

Vol 78 (5) ◽

pp. 255-261 ◽

Cited By ~ 1

Author(s):

Prabhat VARSHNEY ◽

Rizwana PARVEEN ◽

Mohd Ashif KHAN ◽

Sunil KOHLI ◽

Nidhi B. AGARWAL

Keyword(s):

Quality Of Life ◽

Positive Association ◽

Diabetic Patients ◽

Serum Samples ◽

Type 2 Diabetic Patients ◽

Group 3 ◽

Group 2 ◽

Group 1

ABSTRACT Background: Co-morbid diabetes and depression are prevalent chronic conditions negatively affecting quality of life (QoL). Inflammation has been considered as an integral mechanism in patients with both diabetes and depression. Objective: The aim of the present study was to investigate depression and its association with interleukins (IL)-1β and IL-9 in type 2 diabetic patients (T2DM) and controls. The QoL in diabetic patient was also assessed. Methods: Eighty subjects were included, distributed among three groups: Group 1 - Healthy controls; Group 2 - T2DM patients without depression; Group 3 - T2DM patients with depression. Depression and QoL were assessed using Patient Health Questionnaire (PHQ-9) and The Audit of Diabetes-Dependent QoL (ADDQoL), respectively. IL-1β and IL-9 were measured in serum samples of all the patients using ELISA kit. Results: The PHQ score in the Group 3 was significantly higher as compared to Group 1. The ADDQoL scores in the Group 3 were significantly higher as compared to Group 2. Levels of IL-9 and IL-1β were elevated in Group 3, as compared to the other groups. Conclusion: This study showed positive association between depression and IL-1β, IL-9 in T2DM patients. Additionally, the diabetic patients have poorer quality of life, which is further worsened by the presence of depression. Thus, routine assessment for the presence of depression is suggested in T2DM patients.

Download Full-text

Role of Biofilm-Associated Protein Bap in the Pathogenesis of Bovine Staphylococcus aureus

Infection and Immunity ◽

10.1128/iai.72.4.2177-2185.2004 ◽

2004 ◽

Vol 72 (4) ◽

pp. 2177-2185 ◽

Cited By ~ 170

Author(s):

Carme Cucarella ◽

M. Ángeles Tormo ◽

Carles Úbeda ◽

M. Pilar Trotonda ◽

Marta Monzón ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Biofilm Formation ◽

Bovine Mastitis ◽

Serum Samples ◽

Group 3 ◽

Group 2 ◽

Vitro Analysis ◽

Group 1

ABSTRACT Staphylococcus aureus is a common cause of intramammary infections, which frequently become chronic, associated with the ability of the bacteria to produce biofilm. Here, we report a relationship between the ability to produce chronic bovine mastitis and biofilm formation. We have classified bovine mastitis S. aureus isolates into three groups based on the presence of particular genetic elements required for biofilm formation: group 1 (ica + bap +), group 2 (ica +, bap negative), and group 3 (ica negative, bap negative). Overall, animals naturally infected with group 1 and 2 isolates had a lower milk somatic cell count than those infected with isolates of group 3. In addition, Bap-positive isolates were significantly more able to colonize and persist in the bovine mammary gland in vivo and were less susceptible to antibiotic treatments when forming biofilms in vitro. Analysis of the structural bap gene revealed the existence of alternate forms of expression of the Bap protein in S. aureus isolates obtained under field conditions throughout the animal's life. The presence of anti-Bap antibodies in serum samples taken from animals with confirmed S. aureus infections indicated the production of Bap during infection. Furthermore, disruption of the ica operon in a bap-positive strain had no effect on in vitro biofilm formation, a finding which strongly suggested that Bap could compensate for the deficiency of the PIA/PNAG product (a biofilm matrix polysaccharide). Altogether, these results demonstrate that, in the bovine intramammary gland, the presence of Bap may facilitate a biofilm formation connected with the persistence of S. aureus.

Download Full-text

A Comparison Between Different Anti-retroviral Therapy Regimes on Soluble Infammation Markers: a Pilot Study

10.21203/rs.3.rs-36289/v2 ◽

2020 ◽

Author(s):

Martina Maritati ◽

Trentini Alessandro ◽

Nunzia Zanotta ◽

Manola Comar ◽

Tiziana Bellini ◽

...

Keyword(s):

Drug Regimen ◽

Antiretroviral Drugs ◽

Serum Samples ◽

The Third ◽

Cytokines And Chemokines ◽

Antiretroviral Drug ◽

Group 3 ◽

Group 2 ◽

Inflammatory Profile ◽

Group 1

Abstract Background: Although HIV-related deaths have decreased dramatically following the introduction of antiretroviral therapy (ART), HIV infection itself causes increased morbidity and mortality for both non-AIDS-related events or chronic inflammation and immune activation. The use of certain antiretroviral drugs can contribute to this process.Methods: We investigated 26 potential biomarkers in serum samples from HIV-1 infected patients virologically suppressed under ART. The main objective of our study was to evaluate if virological suppression achieved with a triple drug regimen containing tenofovir disoproxil fumarate co-formulated with emtricitabine (TDF/FTC) as backbone, could correlate with a better immunological and inflammatory profile in relation to the third class of antiretroviral drug administered. The eligible patients were then divided into 3 groups in relation to the third drug associated with TDF/FTC: nucleoside reverse transcriptase inhibitors (NNRTI) (Group 1, n=16), protease inhibitors (PI) (Group 2, n=17) and integrase inhibitors (INI) (Group 3, n=16).Results: Inflammatory cytokines and chemokines were more represented in Group 2 than in Group 3 (IL-1Ra, p=0.013; IL-12p70 p=0.039; TNF-α p=0.041; IL-8, p=0.027; MIP1 β, p=0.033). Eotaxin showed lower levels in Group 1 compared to Group 2 (p=0.010), while IP-10 was significantly lower in Group 1 compared to both Group 2 and Group 3 (p=0.003 and p=0.007, respectively).Conclusions: our results seem to discourage the administration of PI as a third drug in a virologically effective antiretroviral regimen, as its use is linked to the detection of higher levels of pro-inflammatory mediators in comparison with INI and NNRTI.

Download Full-text

Evaluation of Novel Immunological Biomarkers as Potential Determinants of Chronic Inflammation in Virologically Suppressed HIV-1 Positive Patients Receiving Antiretroviral Therapy

10.21203/rs.3.rs-36289/v1 ◽

2020 ◽

Author(s):

Martina Maritati ◽

Trentini Alessandro ◽

Nunzia Zanotta ◽

Manola Comar ◽

Tiziana Bellini ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Chronic Inflammation ◽

Drug Regimen ◽

Antiretroviral Drugs ◽

Serum Samples ◽

The Third ◽

Group 3 ◽

Group 2 ◽

Hiv 1 ◽

Group 1

Abstract Background:Although HIV-related deaths have decreased dramatically following the introduction of antiretroviral therapy (ART), HIV infection itself causes increased morbidity and mortality for both non-AIDS-related events or chronic inflammation and immune activation. The use of certain antiretroviral drugs can contribute to this process. Methods:We investigated 26 potential biomarkers in serum samples from HIV-1 infected patients virologically suppressed under ART. The mailobjective of our study was to evaluate if virological suppression achieved with a triple drug regimen containing tenofovir disoproxil fumarate co-formulated with emtricitabine (TDF/FTC) as backbone, could correlate with a better immunological and inflammatory profile in relation to the third class of antiretroviral drug administered. The eligible patients were then divided into 3 groups in relation to the third drug associated with TDF/FTC : NNRTI (Group 1, n=18), + PI (Group 2, n=18) and INI (Group 3, n=18). Results: Traditionally, inflammatory cytokines and chemokines were more represented in Group 2 than in Group 3 (IL-1Ra, p=0.013; IL-12p70 p=0.039; TNF-α p=0.041; IL-8, p=0.027; MIP1 β, p=0.033). Eotaxin showed lower levels in Group 1 compared to Group 2 (p=0.010), while IP-10 was significantly lower in Group 1 compared to both Group 2 and Group 3 (p=0.003 and p=0.007, respectively).Conclusions: our results seem to discourage the administration of PI as a third drug in a virologically effective antiretroviral regimen, as its use is linked to the detection of higher levels of pro-inflammatory mediators than INI and NNRTI.

Download Full-text

CT appearance in the 330 patients with COronaVIrus disease 2019 (COVID-19) in Serbia

Vojnosanitetski pregled ◽

10.2298/vsp200725125k ◽

2020 ◽

pp. 125-125

Author(s):

Tijana Kosanovic ◽

Miroslav Misovic ◽

Vladimir Djukic ◽

Miodrag Lalosevic ◽

Marjana Djordjevic ◽

...

Keyword(s):

Symptom Onset ◽

Time Course ◽

Ct Scans ◽

Time Interval ◽

Imaging Features ◽

Ct Findings ◽

Group 3 ◽

Group 2 ◽

Onset Group ◽

Group 1

Background/Aim. The COronaVIrus Disease 2019 (COVID-19) primarily affects the respiratory system, so radiological diagnosis has been shown to be necessary. Chest computed tomography (CT) is to be shown the best modality in suspected COVID-19 cases for initial evaluation because CT findings may be present before the onset of symptoms. The purpose of this study is to show different CT imaging features or patterns in COVID-19 patients with a different time course and disease severity. Methods. This is a prospective cohort study that analysed 330 patients (the average age was 52.37?15.36) with confirmed COVID-19 via laboratory testing. During hospitalization, all patients included in the study underwent chest CT in order to assess the extent of changes in their lungs. Because chest CT images could show different imaging features or patterns in COVID-19 patients with a different time course and disease severity, we classified them into four categories: lung, bronchial, pleural and mediastinal changes. Based on the time interval between the onset of symptoms and the CT scan, all patients were divided into three groups: group 1 (CT scans done ?1 week after symptom onset); group 2 (CT scans done >1 to 2 weeks after symptom onset); group 3 (CT scans done >2 weeks after symptom onset). In order to more accurately monitor the distribution of changes in the lungs, bilateral lungs were divided into 12 ?lung? zones. Each zone was assigned a CT score. ?Total severity score? was calculated by summing the scores for each zone. Results. In 93.6% patients with COVID-19 the CT findings were positive. About 92.1% patients had multiple lesions. The lesions were bilateral in 87.6% of patients, had both peripheral and centrally localised lesions in 63.3% of patients, and occurred more frequently in posterior areas (93%), as well as in lower lung zones (91.2%). The average ?Total severity score? was 11.00 (7.00-16.00). The most common CT findings in all patients are the ground- glass opacities (97.7%), reticular pattern (91.3%), consolidation (71.5%) and fibrotic streaks (63.8%). When the time interval is monitored between onset of symptoms and the CT scan, it is noticed that in group 1 changes on CT were found in 80.0% of patients, in group 2 in 95.0%, and in group 3 in 99.4%. Conclusion. CT has proven to be a very important diagnostic method in COVID-19 patients, and together with clinical and laboratory findings, gives a complete picture of the patient's condition and significantly contributes to decision- making for further treatment.

Download Full-text

Effect of Non Surgical Periodontal Therapy on Gingival Crevicular Fluid and Serum Visfatin Concentration in Periodontal Health and Disease

Disease Markers ◽

10.1155/2012/828049 ◽

2012 ◽

Vol 32 (6) ◽

pp. 383-388 ◽

Cited By ~ 22

Author(s):

N.M. Raghavendra ◽

A.R. Pradeep ◽

Rahul Kathariya ◽

Anuj Sharma ◽

Nishanth S. Rao ◽

...

Keyword(s):

Chronic Periodontitis ◽

Gingival Crevicular Fluid ◽

Inflammatory Marker ◽

Periodontal Therapy ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Samples ◽

Group 3 ◽

Group 2 ◽

Crevicular Fluid ◽

Group 1

Visfatin is a pleiotropic mediator which acts as growth factor, cytokine, enzyme involved in energy including nicotinamide adenine dinucleotide metabolism and has been recently demonstrated to exert several pro-inflammatory functions. The purpose of this study is to evaluate the Visfatin concentration in gingival crevicular fluid (GCF) and serum in patients with chronic periodontitis, and to evaluate the effect of non-surgical periodontal therapy on the GCF and serum visfatin concentration. 30 subjects (age range: 25 to 52 years) were selected and divided into two groups based on the gingival index, probing depth, periodontal attachment level, and radiologic parameters (bone loss): group 1 (15 subjects with healthy periodontium), group 2 (15 subjects with chronic periodontitis), while, Group 2 patients after 8 weeks of the treatment (scaling and root planning, SRP) constituted group 3. GCF samples (by microcapillary pipettes) and serum samples (by venipuncture) were collected to estimate the levels of Visfatin using enzyme linked immunosorbent assay kit. The mean Visfatin concentration in GCF and serum was observed to be the highest in group 2 and lowest in group 1. While concentration in group 3 was similar to group 1. The concentration of Visfatin in GCF and serum decreased after SRP. The Visfatin concentration in GCF and serum found to be highest in chronic periodontitis group and decreases after treatment. Hence Visfatin values can be considered as an “inflammatory marker” can be explored in future as a potential therapeutic target in the treatment of periodontal disease.

Download Full-text